Read More

Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for

BDRX

Read More

Macy’s Q1 Surprises With Profit Beat And Upgraded Outlook Amid Sales Challenges – Here’s The Scoop

Macy's shares are climbing after reporting better-than-expected Q1 adjusted EPS and raising its FY24 outlook. Despite a 2.7% year-on-year sales decline to $4.846 billion, Macy's adjusted EPS of $0.27 beat the $0.15 consensus. The company updated its FY24 sales forecast to $22.3B-$22.9B and adjusted EPS guidance to $2.55-$2.90, reflecting strong customer response to their new strategy.

M